Natco Pharma Limited has issued a regulatory disclosure to the National Stock Exchange of India Limited and BSE Limited regarding an upcoming board meeting. The meeting of the Board of Directors is scheduled to be held on Wednesday, September 9, 2026.
The primary agenda for the board meeting is to consider the proposal of fund raising by way of equity shares or other securities of the Company. The fundraising would be conducted as permitted under applicable law and is subject to such regulatory/statutory approvals as may be required. The Board will determine what approvals are deemed appropriate.
The disclosure is made pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (SEBI Listing Regulations). The company has requested the exchanges to take this information on record.
The document was signed by Venkat Ramesh Chekuri, digitally signed on September 4, 2026 at 19:00:37 +05:30. The signatory is identified as Ch. Venkat Ramesh, Company Secretary & Compliance Officer of Natco Pharma Limited.
Financial impact of the proposed fundraising is not quantified in the disclosure. Specific details regarding the amount, type of securities, or dilution impact will likely be determined during the board meeting and communicated subsequently.